Publication date: Jul 28, 2026
According to this report, researchers developed PROTEXI, a dendritic cell vaccine that redirects pre-existing antiviral immune memory from SARS-CoV-2 infection to target cancer cells. Preclinical studies in melanoma and breast cancer models demonstrated the vaccine’s ability to reduce tumor burden, enhance the effectiveness of other immunotherapies, and establish long-lasting immune responses. The platform leverages helper T-cell immunity to strengthen cytotoxic T-cell responses, converting previously resistant tumors into more vulnerable targets. Initial clinical trials are planned for patients with sarcoma, suggesting a potential application across various therapy-resistant cancers.
| Concepts | Keywords |
|---|---|
| Antiviral | |
| Celloram | |
| 500 Internal Server Error | Covid |
| Internal Server Error | Existing |
| Helper | |
| Immune | |
| Inc | |
| Memory | |
| Models | |
| Pre | |
| Protexi | |
| System | |
| Tumor | |
| Tumors | |
| Vaccine |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | plan |
| disease | MESH | sarcoma |
| pathway | REACTOME | Immune System |
| disease | MESH | RTs |
| pathway | KEGG | Breast cancer |
| disease | MESH | breast cancer |
| pathway | KEGG | Melanoma |
| disease | MESH | melanoma |
| disease | MESH | infection |
| disease | MESH | severe acute respiratory syndrome |
| pathway | REACTOME | Release |
| disease | MESH | Tumors |
| disease | MESH | COVID-19 |
(Visited 3 times, 1 visits today)